Company Overview - Citizen Health has raised $30 million in Series A funding, bringing total funding to $44 million since its launch in December 2023 [1] - The company is co-founded by Farid Vij and Nasha Fitter, who have extensive experience in AI, healthcare, and patient advocacy [2][5] - Citizen Health aims to empower patients with rare and complex conditions by providing a platform that combines AI, community, and longitudinal health data [2][10] Product and Innovation - The platform is designed to help patients interpret medical records, track symptoms, manage appointments, and connect to the next steps in their health journey [2][3] - Citizen Health plans to launch the first version of its AI Advocate in Q3, targeting select communities [8] - The company has built over 60 engaged communities across 123 rare and complex conditions and partnered with over 70 patient advocacy groups [8] Market Context - Rare diseases affect over 400 million people globally, with 95% lacking approved treatments, highlighting the urgency of Citizen Health's mission [7] - The platform addresses challenges posed by shifting NIH funding and regulatory uncertainty, aligning with recent FDA calls for innovation in rare disease [7] - As genetic testing becomes more accessible, Citizen Health's platform offers critical solutions for new disease groups seeking connection and data-driven progress [7] Partnerships and Trust - Citizen Health collaborates with over 10 pharmaceutical partners and has data accepted by the FDA for regulatory submission [8] - 98.3% of patients on the platform share data for research, indicating a high level of trust in the platform [8] - Investors like 8VC and Headline recognize the potential of Citizen Health in redefining the care model for patients with complex diseases [4][6]

以下文章来源于硅兔君 ，作者Amelie 硅兔君 . 50万创投人关注的硅谷科技风向标 退场大戏上演。 作者 | Amelie 来源 | 硅兔君 （ID：gh_1faae33d0655） 2024倒下的那些科技巨人 新年伊始，这个冬季的裁员潮还在继续。 根据独立裁员追踪机构Layoffs.f y i 的数据，继前两年大幅裁员后，2024年美国457家科技 公司裁员超过13万。特斯拉、亚马逊、谷歌、TikTok、Snap和微软等公司在 2024 年头几 个月进行了大规模裁员；规模较小的初创公司也经历了相当数量的裁员，有些甚至完全关闭了 业务。 同时，2024年美国申请破产的各大小公司接近700家，创近十四年内破产数量新高。 "失败乃成功之母"这句话，我们也许从小到大听过无数遍，但直面真正失败的时候，有多少人 能从中看到通往成功的那些隐喻？尤其是对于任何想要进入商业世界的人来说，了解创业失败 背后的数字和原因甚至比摸索赚钱商机更为重要。虽然有数据显示，90% 的初创公司都失败 了，但这并不意味着你将成为该统计数据的一部分。 2024年，北美的科技创业舞台上，一场接连不断的退场大戏正在上演，科技创业生态系统再 次经 ...

Extends Labcorp's leadership in genetic testing solutions for oncology and select rare diseases BURLINGTON, N.C., Aug. 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of its acquisition of select assets of Invitae (OTC:NVTAQ), a leading medical genetics company. Together, Labcorp and Invitae will support patients, clinicians and pharmaceutical partners across the continuum of care, including therapy development, ...

Updates Full-Year Guidance Results from Continuing Operations for second quarter 2024 versus last year: Revenue: $3.22 billion versus $3.03 billion Diluted EPS: $2.43 versus $1.74 Adjusted EPS: $3.94 versus $3.42 Free Cash Flow: $432.9 million versus $58.2 million Updated Full-Year 2024 Guidance: Revenue range of 6.4% to 7.5%, includes Invitae impact of ~1.0% Adjusted EPS range of $14.30 to $14.90, includes Invitae dilution of ~$0.40 Free Cash Flow of $0.85 billion to $1.00 billion, includes Invitae cash us ...

Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results Invitae has not completed preparation of its financial statements for the fourth quarter or full year 2023. The estimated unaudited financial results presented in this press release for the fourth quarter and full year ended December 31, 2023 are based on Invitae's current expectations and are subject to adjustment. Our independent registered public accounting firm has not audited, reviewed or performed any procedures wi ...

Invitae (NYSE:NVTA) stock fell as much as 78% yesterday before it was ultimately halted because undisclosed news about the firm was pending. Many investors now expect that the SoftBank (OTCMKTS:SFTBY) backed genetic testing specialist will file for bankruptcy before the end of this week.Invitae Is Reportedly Looking to Declare BankruptcyInvitae “is preparing to file for bankruptcy within weeks,” The Wall Street Journal reported late yesterday afternoon, citing unnamed sources. NVTA has hired Kirkland & Elli ...

Medical genetics firm Invitae (NYSE:NVTA) suffered a shocking fall from grace as insider reports point to an upcoming bankruptcy filing. Although the company forwarded a compelling concept — leveraging genetic testing and diagnostics to assess hereditary disease risks — the business model didn’t resonate with customers or investors. As a result, NVTA stock suffered a 75% drop in market value.According to The Wall Street Journal, Invitae’s bankruptcy filing could come within weeks, according to people famili ...

SAN FRANCISCO, Jan. 30, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical need ...

Invitae (NVTA 7.30%) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch a business realignment plan in 2022. The goal was (and is) to speed up the path to positive cash flow, and Invitae has made some progress.Despite efforts, Invitae shares have failed to take off and, instead, have lost more than 80% since the announcement of the new strategy. In fact, they've fallen to such a l ...

SAN FRANCISCO, Jan. 22, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which include carrier screening and non-invasive prenatal screening, to Natera (NASDAQ: NTRA).  The value of the transaction is up to $52.5 million, including cash, milestone payments and litigation credits. Natera has hired Invitae reproductive health sales representatives. In addition, Invitae will transition its non-invasiv ...